Literature DB >> 27312135

Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

Mei Liu1, Zhiyang Li1,2, Jingjing Yang3, Yanyun Jiang3, Zhongsi Chen1, Zeeshan Ali3, Nongyue He1, Zhifei Wang3.   

Abstract

Breast cancer is the second leading cause of cancer death among women, and its related treatment has been attracting significant attention over the past decades. Among the various treatments, targeted therapy has shown great promise as a precision treatment, by binding to cancer cell-specific biomarkers. So far, great achievements have been made in targeted therapy of breast cancer. In this review, we first discuss cell-specific biomarkers, which are not only useful for classification of breast cancer subtyping but also can be utilized as goals for targeted therapy. Then, the innovative and generic-targeted biopharmaceuticals for breast cancer, including monoclonal antibodies, non-antibody proteins and small molecule drugs, are reviewed. Finally, we provide our outlook on future developments of biopharmaceuticals, and provide solutions to problems in this field.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27312135      PMCID: PMC6496337          DOI: 10.1111/cpr.12266

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  192 in total

1.  A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Authors:  Ian E Krop; Patricia LoRusso; Kathy D Miller; Shanu Modi; Denise Yardley; Gladys Rodriguez; Ellie Guardino; Michael Lu; Maoxia Zheng; Sandhya Girish; Lukas Amler; Eric P Winer; Hope S Rugo
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 2.  Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

Authors:  Jessica M Baron; Bonnie L Boster; Chad M Barnett
Journal:  J Oncol Pharm Pract       Date:  2014-03-27       Impact factor: 1.809

Review 3.  Continuous processing for production of biopharmaceuticals.

Authors:  Anurag S Rathore; Harshit Agarwal; Abhishek Kumar Sharma; Mili Pathak; S Muthukumar
Journal:  Prep Biochem Biotechnol       Date:  2015       Impact factor: 2.162

4.  Antiangiogenic therapy in patients with HER2-positive metastatic breast cancer: a case series.

Authors:  Olivia Le Saux; Benoît You; Gilles Freyer
Journal:  Clin Breast Cancer       Date:  2013-11-21       Impact factor: 3.225

5.  Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Authors:  Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 6.  Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.

Authors:  Martin K Schmid; Lucas M Bachmann; Livia Fäs; Alfons G Kessels; Oliver M Job; Michael A Thiel
Journal:  Br J Ophthalmol       Date:  2014-06-11       Impact factor: 4.638

7.  T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.

Authors:  Laura L Michel; Justo Lorenzo Bermejo; Adam Gondos; Frederik Marmé; Andreas Schneeweiss
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

8.  Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Authors:  Jennifer L Spratlin; Roger B Cohen; Matthew Eadens; Lia Gore; D Ross Camidge; Sami Diab; Stephen Leong; Cindy O'Bryant; Laura Q M Chow; Natalie J Serkova; Neal J Meropol; Nancy L Lewis; E Gabriela Chiorean; Floyd Fox; Hagop Youssoufian; Eric K Rowinsky; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

9.  Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

Authors:  G von Minckwitz; S Loibl; M Untch; H Eidtmann; M Rezai; P A Fasching; H Tesch; H Eggemann; I Schrader; K Kittel; C Hanusch; J Huober; C Solbach; C Jackisch; G Kunz; J U Blohmer; M Hauschild; T Fehm; V Nekljudova; B Gerber
Journal:  Ann Oncol       Date:  2014-09-15       Impact factor: 32.976

10.  Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

Authors:  L Arnould; M Gelly; F Penault-Llorca; L Benoit; F Bonnetain; C Migeon; V Cabaret; V Fermeaux; P Bertheau; J Garnier; J-F Jeannin; B Coudert
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  10 in total

Review 1.  PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Authors:  Jill J J Geenen; Sabine C Linn; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

2.  Lanthanide doped carbon dots as a fluorescence chromaticity-based pH probe.

Authors:  Lude Wang; Yang Chen
Journal:  Mikrochim Acta       Date:  2018-10-02       Impact factor: 5.833

Review 3.  Aptamer selection and applications for breast cancer diagnostics and therapy.

Authors:  Mei Liu; Xiaocheng Yu; Zhu Chen; Tong Yang; Dandan Yang; Qianqian Liu; Keke Du; Bo Li; Zhifei Wang; Song Li; Yan Deng; Nongyue He
Journal:  J Nanobiotechnology       Date:  2017-11-13       Impact factor: 10.435

4.  A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer.

Authors:  Jingming Ye; Wenjun Wang; Ling Xu; Xuening Duan; Yuanjia Cheng; Ling Xin; Hong Zhang; Shuang Zhang; Ting Li; Yinhua Liu
Journal:  Chin J Cancer Res       Date:  2017-08       Impact factor: 5.087

5.  Antitumor and antimetastatic activities of a novel benzothiazole-2-thiol derivative in a murine model of breast cancer.

Authors:  XiaoLin Hu; Sen Li; Yan He; Ping Ai; Shaoyong Wu; Yonglin Su; Xiaolin Li; Lei Cai; Xingchen Peng
Journal:  Oncotarget       Date:  2017-02-14

6.  An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.

Authors:  Mei Liu; Zhifei Wang; Ting Tan; Zhongsi Chen; Xianbo Mou; Xiaocheng Yu; Yan Deng; Guangming Lu; Nongyue He
Journal:  Theranostics       Date:  2018-11-10       Impact factor: 11.556

7.  Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.

Authors:  Yan Liu; Yehui Zhou; Kuo-Hsiang Huang; Xujie Fang; Ying Li; Feifei Wang; Li An; Qingfei Chen; Yunchao Zhang; Aihua Shi; Shuang Yu; Jingzhong Zhang
Journal:  Cell Prolif       Date:  2020-06-27       Impact factor: 6.831

Review 8.  Golgi protein 73 and its diagnostic value in liver diseases.

Authors:  Yanyan Xia; Yuanying Zhang; Mengjiao Shen; Hongpan Xu; Zhiyang Li; Nongyue He
Journal:  Cell Prolif       Date:  2018-10-19       Impact factor: 6.831

9.  Nanocarbon Tracer and Areola Injection Site Are Superior in the Sentinel Lymph Node Biopsy Procedure for Breast Cancer.

Authors:  Bo Song; Binming Zhang; Aihu An; Yue Bai; Bo Gao
Journal:  Comput Math Methods Med       Date:  2022-03-14       Impact factor: 2.238

Review 10.  The biogenesis, function and clinical significance of circular RNAs in breast cancer.

Authors:  Yan Zeng; Yutian Zou; Guanfeng Gao; Shaoquan Zheng; Song Wu; Xiaoming Xie; Hailin Tang
Journal:  Cancer Biol Med       Date:  2021-06-10       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.